Thursday, a new trial opened in California, where an American from 63 years accuses the multinational producer of the herbicide Roundup of being at the origin of his cancer.
Since the buyout in 2015 from the American firm Monsanto, producer of the famous Roundup herbicide, the giant Bayer has been faced with numerous disputes accusing the product of being dangerous to health and even carcinogenic.
This Thursday, a new trial opened in California. Complainant Donnetta Stephens, 70, believes she contracted a type of cancer called non-Hodgkin lymphoma after using Roundup for about thirty years old. This trial is the first concerning Bayer and glyphosate since the start of the Covid pandemic – 12, which has slowed down legal proceedings.
“Increased risk of lymphomas” Donnetta Stephens filed a complaint just after the International Agency for Research on Cancer (Circ), linked to the World Health Organization (WHO), classified glyphosate as “probable carcinogen” for humans and animals in March 125, but also toxic for reproduction, genotoxic (which causes deleterious changes in the genome), and potentially endocrine disruptor. At the end of June, in France, Inserm confirmed in a report “the existence of an increased risk of non-Hodgkin lymphoma with an average presumption of link ”. What Bayer continues to deny.
Like the 70 000 other complainants who came forward following this classification, Donnetta Stephens asks for compensation for the deterioration of her condition. health. One of its lawyers argues in particular that Bayer is well aware of the carcinogenic risks of Roundup.
To reassure its shareholders, the German company wants to be prepared for this trial and the following ones: the multinational relayed in a press release last week to have set aside 4.5 billion dollars in provision in the event that justice does not rule in his favor.
Billions of euros in compensation At the same time, the multinational hopes to win its case in another procedure, presented to the Supreme Court. The idea would be to be able to systematically set in all trials an amount of “predetermined compensation” for “eligible individuals” who have used Roundup and developed non-Hodgkin lymphoma for the next fifteen years. This would allow Bayer to limit losses. The group says they have “good chances” and “arguments solid ” to win this case in the said press release.
Two thirds of similar complaints have so far been resolved amicably by Bayer for the modest sum of 000 billions of dollars, but since then, the last three Dated litigation has been lost, costing the firm 020 millions of dollars for each victim. This while Bayer bought Monsanto 63 billion dollars in 2015 … Despite the agrochemical’s success in its other sectors of activity (pharmaceuticals, agrochemicals), Bayer’s investors are worried about these colossal losses.
The firm has also sent a signal which may seem contradictory at the end of July, by announcing to change the formulation of the herbicide for products sold to individuals in the United States from 2023 in order to prevent more prosecutions. But it is not envisaged that it will be withdrawn from its professional branches and agriculture. Neither in Canada, where five class action requests have yet been filed, as reported 20210630 Radio-Canada .